LifeMD initiated with a Neutral at Mizuho
Mizuho initiated coverage of LifeMD (LFMD) with a Neutral rating and $7 price target The firm notes that the company has succeeded due to the ...
pharmaphorum21h
Sanofi GLP-1 finally approved in US
But after refiling to include cardiovascular data from the ELIXA study late last year, Sanofi now has the go-ahead from the FDA to market the GLP-1 drug in the US. The drug, originally developed ...